Category: Press Release - Page 97 - Psychedelic Alpha

Read more about the article MYND Diagnostics Inc. Announces Participation in a Monash University (Australia) Proposal for $3 Million Clinical Trial

MYND Diagnostics Inc. Announces Participation in a Monash University (Australia) Proposal for $3 Million Clinical Trial

Post published:October 13, 2021
Post category:Press Release

Read more about the article atai Life Sciences announces the launch of PsyProtix, to develop a precision psychiatry approach for Treatment-Resistant Depression (TRD)

atai Life Sciences announces the launch of PsyProtix, to develop a precision psychiatry approach for Treatment-Resistant Depression (TRD)

Post published:October 11, 2021
Post category:Press Release

Numinus Upgrades Psychedelics Lab to Increase Research Service Capabilities

Post published:October 8, 2021
Post category:Press Release

Read more about the article Psyched Wellness Announces Commencement of Next Pre-Clinical Study on AME-1

Psyched Wellness Announces Commencement of Next Pre-Clinical Study on AME-1

Post published:October 7, 2021
Post category:Press Release

Read more about the article Tryp Therapeutics Announces Collaboration with Researchers at the University of Wisconsin-Madison

Tryp Therapeutics Announces Collaboration with Researchers at the University of Wisconsin-Madison

Post published:October 7, 2021
Post category:Press Release

Read more about the article MYND Life Sciences Announces Diagnostic Division with Formation of Wholly-Owned Subsidiary – MYND Diagnostics Ltd.

MYND Life Sciences Announces Diagnostic Division with Formation of Wholly-Owned Subsidiary – MYND Diagnostics Ltd.

Post published:October 7, 2021
Post category:Press Release

Read more about the article PharmaTher Initiates Phase 2 Clinical Trial of Ketamine for the Treatment of Parkinson’s Disease

PharmaTher Initiates Phase 2 Clinical Trial of Ketamine for the Treatment of Parkinson’s Disease

Post published:October 6, 2021
Post category:Press Release

Read more about the article Lobe Announces Krysalis VX Innovations Inc., a Company Equally Owned by Lobe Sciences Ltd. and Virtual Psychedelics Incorporated, Appointment of Interdisciplinary Team of Advisors

Lobe Announces Krysalis VX Innovations Inc., a Company Equally Owned by Lobe Sciences Ltd. and Virtual Psychedelics Incorporated, Appointment of Interdisciplinary Team of Advisors

Post published:October 6, 2021
Post category:Press Release

Read more about the article Psygen Announces use of Psilocybin in Human Trial and Provides Update on IP Portfolio

Psygen Announces use of Psilocybin in Human Trial and Provides Update on IP Portfolio

Post published:October 6, 2021
Post category:Press Release

Read more about the article Mydecine To Supply Lead Drug Candidate, MYCO-001, for Multi-Site NIDA Grant-Funded Smoking Cessation Study Lead by Dr. Matthew Johnson

Mydecine To Supply Lead Drug Candidate, MYCO-001, for Multi-Site NIDA Grant-Funded Smoking Cessation Study Lead by Dr. Matthew Johnson

Post published:October 5, 2021
Post category:Press Release

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.